At the news
? MIXEDIMPACT 7/10 8-K filed Feb 24, 2026 at 16:04 ET
BridgeBio Pharma reported strong 2025 financial results driven by $502.1 million in net revenue, primarily from its ATTR-CM drug Attruby, which generated $362.4 million in net product revenue. The company achieved three positive Phase 3 trial readouts, secured $632.5 million in convertible notes, and maintained a robust pipeline with multiple near-term NDA submissions. Despite revenue growth, net loss widened to $724.9 million due to increased commercial and R&D investments.
- Q4 2025 revenue: $154.2 million (up from $5.9 million YoY), full year revenue: $502.1 million (up from $221.9 million YoY)
- Attruby net product revenue: $146.0 million in Q4, $362.4 million for full year 2025
- Three positive Phase 3 readouts: BBP-418 (LGMD2IR9), encaleret (ADH1), and infigratinib (achondroplasia)
- Cash position: $587.5 million as of December 31, 2025, plus $632.5 million from January 2026 convertible notes issuance
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access